Supported by an educational grant from AstraZeneca
Upon completion of this educational activity, participants will be better able to:
- Evaluate the most recent evidence when considering use of a GLP-1 RA as part of a type 2 diabetes mellitus (T2DM) treatment plan
- Review updated safety data for the GLP-1 RA drug class
- Discuss the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors
- Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios
There is no cost to attend, however, seating is limited. Complimentary breakfast or dinner will be provided and all ENDO attendees are welcome. Priority seating will be given to Registration Ticket holders for the first 15 minutes after the advertised start time. If you have not been able to secure a Registration Ticket, the Endocrine Society will have a non-Ticket holder line for general admission to the session on a first-come, first-served basis. Register Now.